Medtronic revenue and financials
$87.09Change from previous close: −1.00%Absolute change: −$0.88
In the fiscal year ended April 2026, Medtronic reported revenue of $36.36B (+8.43% year over year). Net income was $4.8B, a net margin of 13.2%.
Fiscal year ending in April. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +8.43%
- FY to Apr 2026 vs FY to Apr 2025
- Net income growth
- +2.98%
- FY to Apr 2026 vs FY to Apr 2025
- Net margin
- 13.2%
- FY to Apr 2025: 13.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q to Jul 2026 | Q to Apr 2026 | Q to Jan 2026 | Q to Oct 2025 | Q to Jul 2025 | Q to Apr 2025 | Q to Jan 2025 | Q to Oct 2024 | Q to Jul 2024 | Q to Apr 2024 | Q to Jan 2024 | Q to Oct 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 9,756 | 9,807 | 9,017 | 8,961 | 8,578 | 8,927 | 8,292 | 8,403 | 7,915 | 8,589 | 8,089 | 7,984 |
| Cost of revenue | 3,408 | 3,397 | 3,172 | 3,061 | 2,985 | 3,145 | 2,775 | 2,935 | 2,752 | 2,962 | 2,770 | 2,746 |
| Gross profit | 6,348 | 6,410 | 5,845 | 5,900 | 5,593 | 5,782 | 5,517 | 5,468 | 5,163 | 5,627 | 5,319 | 5,238 |
| Selling, general and administrative | 3,166 | 3,043 | 2,927 | 2,939 | 2,778 | 2,700 | 2,693 | 2,727 | 2,626 | 2,526 | 2,624 | 2,624 |
| Research and development | 771 | 671 | 722 | 754 | 726 | 684 | 675 | 697 | 676 | 675 | 695 | 698 |
| Operating income | 1,886 | 2,162 | 1,804 | 1,819 | 1,607 | 1,457 | 1,820 | 1,627 | 1,401 | 1,840 | 1,530 | 1,531 |
| EBIT | 1,886 | 2,162 | 1,804 | 1,819 | 1,607 | 1,457 | 1,820 | 1,627 | 1,401 | 1,840 | 1,530 | 1,531 |
| EBITDA | 2,615 | 2,878 | 2,523 | 2,518 | 2,310 | 2,146 | 2,504 | 2,302 | 2,063 | 2,494 | 2,179 | 2,203 |
| Interest expense | 186 | 176 | 181 | 181 | 176 | 174 | 179 | 209 | 167 | 202 | 188 | 180 |
| Pre-tax income | 1,768 | 1,835 | 1,403 | 1,596 | 1,302 | 1,260 | 1,540 | 1,560 | 1,268 | 856 | 1,472 | 1,313 |
| Income tax | 289 | 575 | 254 | 215 | 255 | 199 | 237 | 281 | 220 | 197 | 135 | 402 |
| Net income | 1,470 | 1,244 | 1,143 | 1,374 | 1,040 | 1,056 | 1,294 | 1,270 | 1,042 | 654 | 1,322 | 909 |
| Net income to common shareholders | 1,470 | 1,244 | 1,143 | 1,374 | 1,040 | 1,056 | 1,294 | 1,270 | 1,042 | 654 | 1,322 | 909 |
| Basic EPS | 1.15 | 0.97 | 0.89 | 1.07 | 0.81 | 0.82 | 1.01 | 0.99 | 0.81 | 0.49 | 0.99 | 0.68 |
| Diluted EPS | 1.14 | 0.97 | 0.89 | 1.07 | 0.81 | 0.82 | 1.01 | 0.99 | 0.80 | 0.49 | 0.99 | 0.68 |
| Average shares (basic) | 1,280 | 1,282 | 1,283 | 1,282 | 1,282 | 1,282 | 1,282 | 1,282 | 1,293 | 1,322 | 1,330 | 1,330 |
| Average shares (diluted) | 1,285 | 1,288 | 1,290 | 1,288 | 1,287 | 1,288 | 1,286 | 1,287 | 1,297 | 1,325 | 1,332 | 1,332 |
| Dividend per share | 0.72 | 0.71 | 0.71 | 0.71 | 0.71 | 0.70 | 0.70 | 0.70 | 0.70 | 0.69 | 0.69 | 0.69 |
